Laboratory Testing Core

实验室测试核心

基本信息

  • 批准号:
    8247047
  • 负责人:
  • 金额:
    $ 22.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

Core B: Laboratory Testing Core The Testing Laboratory Core B has the goal to serve every project in the Program. It will provide an array of assays assessing fibrinolysis, coagulation, anticoagulant activities, and plasma lipid profiles. The Core will also provide assays of inflammatory cytokines, and adipokines as well as with established kits for mouse proteins associated with thrombosis, atherosclerosis and obesity. The specific assays that are available for each of the projects are indicated below. Core B will also coordinate the high through-put screening of small molecules by the Center for Chemical Genomics. Project 1: Core B will perform analysis of plasma PAI-1 levels for both active and inactive PAI-1 and of plasminogen activator antigen and activity levels. In addition, plasma lipid profiles will be routinely determined and immunoassays of various inflammatory cytokines as well as adipokines will be measured in a mutiplex format using the Luminex Technology. High through-put screening of small molecule compound libraries for the development of novel PAI-1 inactivating agents will also be performed through the Center for Chemical Genomics. Project 2: Core B will perform analysis of plasma PAI-1 levels for both active and inactive PAI-1 and of plasminogen activator antigen and activity levels. Murine plasmas will also be analyzed for increased risk for thrombosis by determining the levels of plasma coagulation, and anticoagulant proteins in various strains of mice at baseline, and after venous thrombosis with or without hypercholesterolemia. D-dimer levels will also be measured. Procoagulant microparticles will also be measured as well as immunoassays of various inflammatory cytokines. Project 3: Core B will assist the investigators off Project 3 by assessing platelet function including bleeding times and platelet aggregation in mice. Fibrinolytic parameters will be determined including PAI-1 and plasminogen activator levels. Immunoassays of various inflammatory cytokines will also be measured in a mutiplex format using the Luminex Technology. Project 4: Core B will assist the investigators of Project 4 by developing novel, assays for coagulation/fibrinolysis and platelet function in Zebrafish. These assays will include immunoassays and functional assays such as clotting times as well as factor assays. The overall goals of the Testing Laboratory Core B are to enhance the success of each individual project by providing rigorous, standardized assays and to ensure that the combined Program is stronger than each of its individual parts.
核心B:实验室测试核心 测试实验室核心B的目标是为项目中的每个项目提供服务。它将提供一个 评估纤维蛋白溶解、凝血、抗凝活性和血浆脂质分布的测定。芯会 还提供了炎性细胞因子和脂肪因子的测定以及用于小鼠的已建立的试剂盒, 与血栓形成、动脉粥样硬化和肥胖症相关的蛋白质。可用于以下目的的特定检测试剂盒 每个项目如下。核心B也将协调小的高通量筛选 化学基因组学中心(Center for Chemical Genomics) 项目1:核心B将分析活性和非活性派-1的血浆派-1水平, 纤溶酶原激活物抗原和活性水平。此外,还将常规检测血脂谱。 测定和免疫测定各种炎性细胞因子以及脂肪因子, 使用Luminex技术的多路复用格式。小分子化合物的高通量筛选 用于开发新型派-1灭活剂的文库也将通过 化学基因组学 项目2:核心B将分析活性和非活性派-1的血浆派-1水平, 纤溶酶原激活物抗原和活性水平。还将分析鼠血浆中的以下风险增加: 血栓形成通过测定血浆凝固水平,和抗凝蛋白在各种菌株, 在基线和静脉血栓形成后,有或没有高胆固醇血症的小鼠。D-二聚体水平也将 被衡量。还将测量促凝血剂微粒以及各种促凝血剂的免疫测定。 炎性细胞因子 项目3:核心B将通过评估血小板功能(包括出血)协助研究者退出项目3 时间和小鼠血小板聚集。将测定纤溶参数,包括派-1和 纤溶酶原激活物水平。各种炎性细胞因子的免疫测定也将在免疫组织化学中测量。 使用Luminex技术的多路复用格式。 项目4:核心B将协助项目4的研究者开发新的检测方法, 凝血/纤维蛋白溶解和血小板功能。这些测定将包括免疫测定和 功能测定如凝血时间以及因子测定。 测试实验室核心B的总体目标是通过以下方式提高每个项目的成功率 提供严格、标准化的检测,并确保合并后的计划比 它的各个部分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel A Lawrence其他文献

Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages
纤溶酶原促进肉瘤生长并抑制肿瘤浸润巨噬细胞的积累
  • DOI:
    10.1038/sj.onc.1205951
  • 发表时间:
    2002-12-16
  • 期刊:
  • 影响因子:
    7.300
  • 作者:
    Alejandro Curino;David J Mitola;Hannah Aaronson;Grainne A McMahon;Kamran Raja;Achsah D Keegan;Daniel A Lawrence;Thomas H Bugge
  • 通讯作者:
    Thomas H Bugge

Daniel A Lawrence的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel A Lawrence', 18)}}的其他基金

Characterization and targeting of a novel pathway promoting Parkinson’s Disease
促进帕金森病的新途径的表征和靶向
  • 批准号:
    10855706
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
A Novel PAI-1 Function Drives Lung Fibrosis
PAI-1 的新功能可驱动肺纤维化
  • 批准号:
    10605479
  • 财政年份:
    2022
  • 资助金额:
    $ 22.77万
  • 项目类别:
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology
PAI-1 在脑微血管功能障碍和阿尔茨海默病发展中的作用 神经病理学
  • 批准号:
    10314556
  • 财政年份:
    2021
  • 资助金额:
    $ 22.77万
  • 项目类别:
The Role of PAI-1 in Cerebral Microvascular Dysfunction and the Development of Alzheimer’s Disease Neuropathology
PAI-1 在脑微血管功能障碍和阿尔茨海默病发展中的作用 神经病理学
  • 批准号:
    10629303
  • 财政年份:
    2021
  • 资助金额:
    $ 22.77万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8655918
  • 财政年份:
    2012
  • 资助金额:
    $ 22.77万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8487469
  • 财政年份:
    2012
  • 资助金额:
    $ 22.77万
  • 项目类别:
Mechanism of thrombolytic tPA induced intracerebral hemorrhage after stroke
溶栓tPA致脑卒中后脑出血的机制
  • 批准号:
    8345099
  • 财政年份:
    2012
  • 资助金额:
    $ 22.77万
  • 项目类别:
Characterization of the role of PAI-1 in lipid metabolism
PAI-1 在脂质代谢中的作用表征
  • 批准号:
    8247042
  • 财政年份:
    2011
  • 资助金额:
    $ 22.77万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8247048
  • 财政年份:
    2011
  • 资助金额:
    $ 22.77万
  • 项目类别:
Laboratory Testing Core
实验室测试核心
  • 批准号:
    8150067
  • 财政年份:
    2010
  • 资助金额:
    $ 22.77万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 22.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了